E7820
Sponsors
Eisai Inc., Memorial Sloan Kettering Cancer Center
Conditions
Acute Myeloid LeukemiaAdvanced Solid TumorsChronic Myelomonocytic LeukemiaColon CancerColorectal CancerLymphoma, MalignantMyelodysplastic SyndromesNeoplasms
Phase 1
Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma
CompletedNCT00078637
Start: 2004-01-31End: 2007-02-28Updated: 2014-12-23
FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
TerminatedNCT01133990
Start: 2010-03-04End: 2011-02-18Updated: 2023-11-07
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
TerminatedNCT01347645
Start: 2011-09-30End: 2015-06-22Updated: 2023-06-22
An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors
CompletedNCT01773421
Start: 2011-06-30End: 2017-11-12Updated: 2023-06-22